# A Randomized Controlled Trial of Prophylactic Rituximab to Reduce Clinically Significant EBV DNAemia After Allogeneic Hematopoietic Stem Cell Transplantation

> **NCT07703657** · NA · NOT_YET_RECRUITING · sponsor: **Yang Donglin** · enrollment: 168 (estimated)

## Conditions studied

- Allogeneic Hematopoietic Stem Cell Transplantation
- Epstein-Barr Virus Reactivation
- Clinically Significant EBV DNAemia

## Interventions

- **DRUG:** Rituximab (Arm A)
- **OTHER:** Standard Post-Transplant Supportive Care

## Key facts

- **NCT ID:** NCT07703657
- **Lead sponsor:** Yang Donglin
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-09
- **Primary completion:** 2027-07-09
- **Final completion:** 2027-07-09
- **Target enrollment:** 168 (ESTIMATED)
- **Last updated:** 2026-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07703657

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07703657, "A Randomized Controlled Trial of Prophylactic Rituximab to Reduce Clinically Significant EBV DNAemia After Allogeneic Hematopoietic Stem Cell Transplantation". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07703657. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*